Search

You searched for "conference"

687 results found

Convatec Healthcare is changing

11 May 2023
Forever Caring At Convatec, ‘forever caring’ is our promise to give patients and healthcare providers the support they need as we bring to life our vision of pioneering trusted medical solutions to improve the lives we touch. Existing complications of...

Assessment and management of percutaneous nephrostomies

8 January 2024 | | URO - Trauma & Emergency, URO - Uroradiology
Nephrostomies are a valuable uroradiological intervention which enables drainage of the obstructed kidney, amongst other indications. Complications associated with nephrostomies following placement are not uncommon, with re-presentation to the emergency department or surgical emergency unit. In this review we will...

Penile Mondor’s disease

1 January 2019 | | URO - Andrology
Mondor’s disease is a rare, self-limiting entity characterised by subcutaneous chord like bands throughout the body. These bands arise due to phlebitis of the subcutaneous vessels. Penile Mondor’s disease (PMD) is an isolated superficial thrombophlebitis of the superficial dorsal vein...

Balanitis xerotica obliterans

1 September 2018 | | URO - Andrology, URO - Urologic Oncology
Balanitis xerotica obliterans (BXO) / lichen sclerosus of the male genitalia is a common cause of acquired phimosis, and was first described by Stuhmer in 1928 [1]. It is described in medical literature as a chronic inflammatory condition of unknown...

Understanding Stauffer’s syndrome

1 May 2018 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Functional / Reconstructive Urology, URO - Infection, URO - Neurourology, URO - Paediatric Urology, URO - Technology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...

Molecular biology – bladder cancer

1 January 2014 | | URO - Basic Science Research, URO - Urologic Oncology
Background Bladder cancer is the most common cancer of the urinary tract and approximately 90% of bladder cancers diagnosed in North America and Europe are transitional cell carcinomas (TCC). For the purposes of diagnosis and treatment, bladder cancer is often...

A guide to local anaesthetic transperineal prostate biopsy

2 November 2023 | | URO - Urologic Oncology
In the UK, nearly 100,000 men undergo a prostate biopsy annually, a figure projected to double in the next decade [1]. In recent years, we have observed a paradigm shift in urological practice in numerous UK hospitals. The conventional transrectal,...

Post radical nephrectomy presenting with skull metastasis

10 April 2024 | | URO - Urologic Oncology
We present the case of an 83-year-old female who underwent right radical nephrectomy for renal cell carcinoma (RCC). Despite negative surgical margins, the patient presented with a skull metastasis six years post radical nephrectomy. This case highlights the importance of...

Urine leak post partial nephrectomy: a case for lower tract before upper tract

4 June 2025 | | URO - Core Urology, URO - Urologic Oncology, URO - Uroradiology
Partial nephrectomy has become the standard of care in the management of small renal masses. It is a vital tool in maximising nephron preservation and oncological control for patients. It has been shown to produce equivalent oncological outcomes to radical...

In conversation with Ian Pearce

21 August 2024 | URO - Core Urology
We were delighted to catch up with our old friend, Ian Pearce, former Editor of Urology News and new President of BAUS. Can you tell us a little bit about what led you into the field of urology and the...

Kidney stones in pregnancy

2 November 2023 | | URO - Endourology & Stones
Case 1 A 28-year-old female, 19 weeks pregnant, presents with severe left loin pain. There is no past medical history of note. Blood tests show a white cell count of 14.1x109/L and creatinine of 56umol/L. An ultrasound scan (USS) reports...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...